France's Ipsen Q3 sales rise 28% driven by core portfolio

By Reuters News


Overview

  • France-based biopharma's Q3 sales rose 28%, driven by core portfolio

  • Company raised full-year 2026 sales growth and margin guidance

  • Company completed acquisitions of Memo Therapeutics and Kartos Therapeutics in Q3


Outlook

  • Ipsen now sees 2026 total sales growth around 23.0% at CER, up from >20.0%

  • Company raises core operating margin to around 39.0% from to >37.0%

  • Guidance assumes strong double-digit growth in core portfolio and Somatuline despite generic entry


Result Drivers

  • CORE PORTFOLIO AND SOMATULINE - Co said Q3 results were driven by strength of its core portfolio and continued growth of Somatuline, per CEO David Loew

  • PIPELINE EXPANSION - Acquisitions of Memo Therapeutics and Kartos Therapeutics in Q3 strengthened Rare Disease and Oncology pipelines


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

EUR 1.17 bln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and 3 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Ipsen SA is €160.00, about 5.1% above its October 21 closing price of €152.20

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 13 three months ago


Reuters Recommended Reads

  • Oct 20 - France's EssilorLuxottica Q3 revenue rises on wearables, myopia management portfolio growth

  • Oct 19 - France's Virbac Q3 revenue rises on strength in Both Companion Animal, Farm Animal segments

  • Oct 20 - Novo's CagriSema helped women lose 25% of weight on average, analysis shows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.